CME Clinical pharmacology and sulfones, nitrofurantoin, nalidixic acid, quinine, flutamide
and methylthioninium chloride. Phenotypic tests for G6PD deficiency are recommended …

Long before the term pharmacogenetics was coined, it was recognized that patients respond
very differently to treatment with a drug. Indeed, the question how variability of drug …

Pharmacogenetics (PGx) is not a silver bullet. Not every patient benefits from a PGx test.
There are still many hurdles and barriers that need to be overcome and new knowledge that …

Ingelman‐Sundberg M (IMM, Karolinska Institutet, Stockholm, Sweden). Pharmacogenetics:
an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186 …

Background PGx is the understanding and extrapolation of variations in the patient's
underlying DNA into therapeutic recommendations or more simply use of a patient's specific …

A genetic evaluation should be considered for any unusual constellation of findings that
perplexes the primary care provider or other subspecialist, known entity associated with …

Ineffective treatments and adverse drug effects account for much preventable morbidity and
expense. New treatments, touted as more potent, are often introduced as replacements for …

Despite initial enthusiasm, 1, 2, 3 the use of pharmacogenetics has remained limited to
investigation in only a few clinical fields such as oncology and psychiatry. 4, 5, 6, 7, 8 The …

The dawn of the new millennium saw numerous articles (particularly in the lay and financial
press) on the promise of pharmacogenetics and personalized drug therapy. These articles …

Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency is associated with development of
acute hemolytic anemia in the setting of oxidative stress, which can be caused by …